TNFRSF17 and astrocytoma (excluding glioblastoma): Our study may help pave the way toward clinical application of BCMA-targeted fourth-generation CAR-T cells and thus highlight a potential strategy for dealing with malignancies of BCMA overexpression such as Waldenstrom macroglobulinemia and glioblastoma/astrocytoma (57, 58).